Operating Income: The income after operating expenses.
BridgeBio Pharma, Inc. (BBIO) had Operating Income of $-145.20M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$120.70M |
|
$-182.74M |
|
$6.56M |
|
$114.14M |
|
$265.90M |
|
|
Operating Income |
$-145.20M |
$-41.28M |
|
$-186.48M |
|
$-186.48M |
|
$-184.94M |
|
$-184.94M |
|
$-184.94M |
|
$-184.94M |
|
$-145.20M |
|
$-143.80M |
|
191.85M |
|
191.85M |
|
$-0.95 |
|
$-0.95 |
|
| Balance Sheet Financials | |
$839.38M |
|
$5.83M |
|
$158.87M |
|
$998.25M |
|
$216.60M |
|
$1.85B |
|
$2.70B |
|
$2.92B |
|
$-1.92B |
|
$-1.95B |
|
$-1.92B |
|
192.63M |
|
| Cash Flow Statement Financials | |
$-389.49M |
|
$-10.13M |
|
$361.48M |
|
$683.24M |
|
$645.10M |
|
$-38.15M |
|
$98.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.88 |
|
-- |
|
-- |
|
-25.80 |
|
-0.96 |
|
94.56% |
|
-120.30% |
|
-120.30% |
|
-- |
|
-154.50% |
|
-151.40% |
|
$-390.55M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.27 |
|
1.04 |
|
86.88 |
|
9.62% |
|
9.48% |
|
-18.53% |
|
257.80% |
|
$-9.98 |
|
$-2.04 |
|
$-2.03 |
|